Lexaria Bioscience Corp. (NASDAQ: LEXX) has remained committed to enhancing the speed and overall efficiency of orally delivered fat-soluble active molecules. The company is leveraging its drug delivery technology, DehydraTECH(TM), in the development of hypertension and anti-viral treatments — a big achievement already making an impact in the pharmaceutical industry. “Since Lexaria began working on this technology in 2014, DehydraTECH has developed considerably and impacted the industry. So far, it has proven useful for potentially treating hypertension, along with the delivery of colchicine, a drug with known SARS-CoV-2 anti-viral properties,” reads a recent article. “DehydraTECH is applied by incorporating an intermediate step in the formulation and manufacturing of existing or orally ingestible and topical products. This is a crucial step that entails mixing the active ingredients as a delivery ‘payload’ with specific fatty acids and infusing the mixture into a substrate material. The next step involves using a controlled dehydration synthesis processing to associate the payload and fatty acids together at a molecular level before integrating the newly combined molecules into end-product production across various dosage form factors. From a commercial standpoint, Lexaria’s technology is proving to provide an additional layer that companies that offer consumer supplements, prescription, and non-prescription-based drugs, cannabis, and nicotine products can use to improve the effectiveness of both new and existing products.”
To view the full article, visit https://ibn.fm/tPlMX
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp.’s patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by up to 5-10x, reduce time of onset from 1-2 hours to minutes and mask unwanted tastes; it is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (“NSAIDs”) and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 21 patents granted and over 50 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
